local_hospital

Azienda Ospedaliera Nazionale Ss Antonio E Biagio E C Arrigo Alessandria

Address
Via Venezia 16, 15121 Alessandria, Italy

Cardiovascular Diseases

At Azienda Ospedaliera Nazionale Ss Antonio E Biagio E C Arrigo Alessandria, cardiovascular research focuses on preventing major heart and stroke events in people with acute coronary syndrome. These studies are designed to test whether new treatment approaches can improve protection beyond standard care.

  • Reducing the risk of cardiovascular death, heart attack, and ischemic stroke
  • Evaluating a new therapy added to usual treatment after a cardiac event

This work reflects a strong interest in better long-term outcomes for patients with serious heart disease.

Neoplasms and Hemic/Lymphatic Diseases

Much of the clinical trial activity at this site centers on lymphomas and other blood cancers, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and multiple myeloma. The research aims to improve treatment effectiveness, support patients who are less fit for standard therapy, and explore better ways to control relapsed or newly diagnosed disease.

  • Testing new immunotherapy and antibody-based treatments for lymphoma
  • Studying response-adapted care for patients with newly diagnosed or hard-to-treat blood cancers
  • Evaluating treatment options for relapsed or refractory multiple myeloma

These studies highlight the site’s active role in advancing care across aggressive and indolent hematologic malignancies.

Digestive System Diseases and Inflammatory Conditions

Clinical research here also includes ulcerative colitis, with trials focused on improving clinical remission for people living with chronic intestinal inflammation. The goal is to assess whether new treatments can better control symptoms and support longer-lasting disease management.

  • Evaluating a new therapy for ulcerative colitis
  • Comparing its ability to achieve and maintain clinical remission

These studies add an important gastroenterology dimension to the site’s broader research portfolio.

Nutritional and Metabolic Diseases

In the area of gout with hyperuricemia, the site is involved in research aimed at lowering uric acid levels more effectively. This work is intended to compare a new treatment approach with established care and improve symptom control for patients affected by metabolic complications.

  • Comparing treatments for better uric acid reduction
  • Supporting improved management of gout and related metabolic risk

Such studies help refine everyday treatment strategies for a common and painful chronic condition.

Pathological Conditions, Signs and Symptoms

This research area includes studies on reversing the effects of factor Xa inhibitors in patients who need urgent surgery and face a major bleeding risk. The objective is to evaluate whether a targeted treatment can help control bleeding more effectively than usual care in emergency settings.

  • Assessing rapid reversal of anticoagulation-related bleeding risk
  • Supporting safer urgent procedures for patients on blood thinners

These trials address a practical hospital need and may improve emergency management for high-risk patients.

Musculoskeletal Diseases

The site also contributes to research in musculoskeletal disease, particularly by studying conditions such as gout that affect joints and mobility. The aim is to improve symptom relief and long-term disease control through better treatment options.

  • Improving care for joint-related complications linked to gout
  • Comparing treatments that may reduce inflammation and discomfort

This work supports more effective management of painful conditions that can interfere with daily activity.

Health Care and Public Health

Some of the research at this hospital addresses broader health care needs, including safer treatment pathways and better support for patients with complex conditions. These studies focus on practical improvements that can strengthen care delivery in real-world clinical settings.

  • Improving safety in urgent and high-risk hospital care
  • Testing new approaches that may enhance treatment effectiveness across specialties

By combining specialty research with applied health care questions, the site contributes to both individual patient care and broader clinical practice.

Site Overview

assignment
134
connected trials
corporate_fare
80
sponsors
science
240
IMPs

Activity Indicator

Last 6 months

10
Trials started
-9% vs previous period.
11
Trials started 6–12 months ago
134
Total trials linked
Highly Active
trending_downDeclining-9%
2
3
2
2
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 16 therapeutic areas and 15 of 240 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 218 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
71
Sponsors (total)
80
Active sponsors
52

Sponsor Network

Top 52 by active trials.

lock +51 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +19 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 566 other sites in Italy

description
Trial volume
134
Outperforms 91% of sites
public
Therapeutic diversity
16areas
Outperforms 90% of sites
groups
Sponsor diversity
80sponsors
Outperforms 92% of sites

Therapeutic Area Benchmark — Italy

Select a therapeutic area to compare against other sites in Italy.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Italy

Market Share

Country: Italy

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Azienda Ospedaliera Nazionale Ss Antonio E Biagio E C Arrigo Alessandria

lock Showing 1 of 134 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Multicenter, Open-label, Phase 2 Dose Escalation and Confirmation, and Efficacy Expansion Study of Zilovertamab Vedotin (MK-2140) in Combination with R-CHP in Participants with DLBCL (waveLINE)Merck Sharp & Dohme LLCPhase IINot RecruitingAug 2022

IMP list

lock Showing 1 of 240 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Rituximab21Unknown2014-03-242025-09-03

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.